<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630978</url>
  </required_header>
  <id_info>
    <org_study_id>2018.01</org_study_id>
    <nct_id>NCT03630978</nct_id>
  </id_info>
  <brief_title>Impact of Sarcopenia on Postoperative Outcomes of Patients Undergoing Liver Resection</brief_title>
  <official_title>The Impact of Sarcopenia, Body Composition and Other Biometric Parameters on the Postoperative Outcomes of Patients Undergoing Liver Resection for Different Indications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Camillo Hospital, Rome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>San Camillo Hospital, Rome</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will investigate the impact of different biometric parameters (Body mass
      index, sarcopenia, lean muscle mass, hand-grip strength, gait speed, fat composition) on the
      postoperative outcomes of patients undergoing liver resections.

      Major and minor liver resections will be considered as well as open and minimally invasive
      techniques.

      Benign and malignant indications will be included. Patients characteristics and perioperative
      variables will be considered for analysis.

      Short-term outcomes will be evaluated focusing on 90-days morbidity and mortality and
      readmission rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the null hypothesis, no difference in postoperative morbidity between the two
      groups would be expected. To calculate sample size, a 42% morbidity rate would be expected in
      sarcopenic patients while a 22% rate would be expected in the non-sarcopenic group.
      Considering a two-sided α=0.05 and β=0.1, the minimal sample size required to achieve
      statistical significance was 224 subjects. Considering a 10% drop-out rate of patients
      undergoing explorative laparoscopy or laparotomy without parenchymal resection a total of 249
      patients will be required for completion of the study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity</measure>
    <time_frame>within 90 days after surgery</time_frame>
    <description>Patients experiencing medical or surgical complications after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>within 90 days after surgery</time_frame>
    <description>Patients dying after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission rate</measure>
    <time_frame>within 90 days after discharge</time_frame>
    <description>patients readmitted to hospital after discharge</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">251</enrollment>
  <condition>Liver Neoplasms</condition>
  <condition>Sarcopenia</condition>
  <condition>Postoperative Complications</condition>
  <arm_group>
    <arm_group_label>Liver resection</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver resection</intervention_name>
    <description>Major or minor, open or laparoscopic liver resection</description>
    <arm_group_label>Liver resection</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing liver resection for benign and malignant indications with CT scan
        imaging availability within 30 days before surgery.

        Of all the patients included in the study muscle function tests will be collected including
        handgrip strength, gait speed and fat composition.

        Preoperative antropometric, biochemical and disease presentation characteristics will be
        collected as well as operative details and postoperative outcomes.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients undergoing open or laparoscopic liver resection

          2. Patients undergoing major or minor liver resection

          3. Patients undergoing liver resection for primary or secondary liver malignancies

          4. Patients undergoing liver resections for benign diseases (cysts, adenoma, focal
             nodular hyperplasia, hemangioma) -

        Exclusion Criteria:

          1. Patients undergoing extrahepatic resection

          2. Patients undergoing cyst fenestration or biopsies without liver resections

          3. Patients with extrahepatic metastases

          4. Patients undergoing explorative laparoscopy or laparotomy without parenchymal
             transection -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Maria Ettorre, Prof</last_name>
    <role>Study Director</role>
    <affiliation>San Camillo Hospital Spallanzani</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Camillo Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Zhang G, Meng S, Li R, Ye J, Zhao L. Clinical significance of sarcopenia in the treatment of patients with primary hepatic malignancies, a systematic review and meta-analysis. Oncotarget. 2017 Jul 28;8(60):102474-102485. doi: 10.18632/oncotarget.19687. eCollection 2017 Nov 24.</citation>
    <PMID>29254263</PMID>
  </results_reference>
  <results_reference>
    <citation>Harimoto N, Yoshizumi T, Izumi T, Motomura T, Harada N, Itoh S, Ikegami T, Uchiyama H, Soejima Y, Nishie A, Kamishima T, Kusaba R, Shirabe K, Maehara Y. Clinical Outcomes of Living Liver Transplantation According to the Presence of Sarcopenia as Defined by Skeletal Muscle Mass, Hand Grip, and Gait Speed. Transplant Proc. 2017 Nov;49(9):2144-2152. doi: 10.1016/j.transproceed.2017.09.017.</citation>
    <PMID>29149975</PMID>
  </results_reference>
  <results_reference>
    <citation>Simonsen C, de Heer P, Bjerre ED, Suetta C, Hojman P, Pedersen BK, Svendsen LB, Christensen JF. Sarcopenia and Postoperative Complication Risk in Gastrointestinal Surgical Oncology: A Meta-analysis. Ann Surg. 2018 Jul;268(1):58-69. doi: 10.1097/SLA.0000000000002679.</citation>
    <PMID>29373365</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 11, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>December 22, 2019</last_update_submitted>
  <last_update_submitted_qc>December 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Camillo Hospital, Rome</investigator_affiliation>
    <investigator_full_name>Giammauro Berardi</investigator_full_name>
    <investigator_title>Resident in Surgery, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>colorectal liver metastases</keyword>
  <keyword>non-colorectal liver metastases</keyword>
  <keyword>focal nodular hyperplasia</keyword>
  <keyword>liver hemangioma</keyword>
  <keyword>liver cysts</keyword>
  <keyword>surgical morbidity</keyword>
  <keyword>surgical mortality</keyword>
  <keyword>sarcopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

